Piper Sandler Raises Enfusion (NYSE:ENFN) Price Target to $11.50

Enfusion (NYSE:ENFN) had its price objective hoisted by investment analysts at Piper Sandler from $10.00 to $11.50 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Piper Sandler’s price target indicates a potential upside of 8.70% from the company’s current price.

Separately, Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.25.

Enfusion Stock Up 0.6 %

ENFN stock opened at $10.58 on Monday. The company has a 50-day simple moving average of $9.74 and a 200 day simple moving average of $9.02. The company has a market capitalization of $1.36 billion, a P/E ratio of 264.57, a PEG ratio of 3.98 and a beta of 0.97. Enfusion has a fifty-two week low of $7.52 and a fifty-two week high of $11.38.

Insider Activity at Enfusion

In related news, COO Neal Pawar sold 21,801 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now directly owns 1,143,544 shares of the company’s stock, valued at $11,469,746.32. This represents a 1.87 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 36.44% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Centiva Capital LP boosted its stake in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock worth $243,000 after acquiring an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after purchasing an additional 1,315 shares during the last quarter. Azora Capital LP lifted its holdings in shares of Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after purchasing an additional 1,890 shares during the last quarter. 272 Capital LP boosted its position in shares of Enfusion by 1.5% in the 2nd quarter. 272 Capital LP now owns 139,180 shares of the company’s stock valued at $1,186,000 after purchasing an additional 2,000 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in Enfusion by 27.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after purchasing an additional 4,239 shares in the last quarter. Institutional investors and hedge funds own 81.05% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.